Alexandra Leary, MD, PhD, Gustave Roussy Institute, Villejuif, France, provides an outlook onto the near future of precision oncology in endometrial cancer, including moving immune checkpoint inhibitors in earlier settings, and a greater understanding of endometrial cancer molecular subtypes. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.